Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

H. Lundbeck A/S HLUYY OTC

Other OTC • Healthcare • Drug Manufacturers - Specialty & Generic • DK • USD

SharesGrow Score
44/100
0/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

H. Lundbeck A/S (HLUYY) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $22.00. It has a SharesGrow Score of 43/100, indicating a mixed investment profile with 0 out of 7 criteria passed.

Financials: revenue is $16.3B, -3%/yr average growth. Net profit margin is 0% (thin). Gross margin is 77.6% (-3.1 pp trend).

Balance sheet: total debt is $5.3B against $18.3B equity (Debt-to-Equity (D/E) ratio 0.29, conservative). Current ratio is 0.98 (tight liquidity). Total assets: $0.

Analyst outlook: 0 / 1 analysts rate HLUYY as buy (0%) — mixed sentiment.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 75/100 (Partial), Health 67/100 (Partial), Moat 57/100 (Partial), Future 20/100 (Fail), Income 30/100 (Fail).

HLUYY SharesGrow Score Overview

44/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 75/100
strong — trend
HEALTH 67/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 57/100
Gross margin is + market cap
FUTURE 20/100
Analyst outlook — as buy
INCOME 30/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — HLUYY

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
HLUYY: -3%/yr revenue is, -57.5%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
~
PAST Partial
75/100
HLUYY: 3 / 4 years profitable. mixed. Score = 3 / 4 × 100. ≥ 80 = Pass.
View details →
~
HEALTH Partial
67/100
Balance sheet HLUYY: Debt-to-Equity (D/E) ratio 0.29 (conservative), Current ratio is 0.98 (tight liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
57/100
HLUYY: Gross margin is 77.6% (-3.1 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 57/100. ≥ 70 = Pass.
View details →
✗
FUTURE Fail
20/100
Analyst outlook: 0 / 1 analysts rate HLUYY as buy (0%). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
30/100
HLUYY: Net profit margin is 0%. thin (0-5%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range22-22
Volume7.54K
Avg Volume (30D)1.79K
Beta (1Y)0.61
Dividend Yield$4.7350
Share Statistics
Shares Outstanding$198.66M
IPO Date2012-05-21
Employees5,353
CEODeborah Dunsire
Financial Highlights & Ratios
Revenue (TTM)$16.3B
Gross Profit$12.65B
EBITDA$3.72B
Operating Income$2.01B
Total Cash$2.28B
Total Debt$5.32B
Net Debt$3.04B
Analyst Forecast
Rating ConsensusHold
Analysts Covering1
Buy 0% Hold 100% Sell 0%
Company Info
CountryDK
ExchangeOther OTC
CurrencyUSD
ISINUS40422M2061

Price Chart

Track all markets on TradingView
HLUYY
H. Lundbeck A/S ↗  ·  Other OTC
Healthcare • Drug Manufacturers - Specialty & Generic

People Also View

LLY
LLY
Eli Lilly and Company
$905.13
-1.88%
 JNJ
JNJ
Johnson & Johnson
$238.67
-0.60%
 ABBV
ABBV
AbbVie Inc.
$208.43
-0.87%
 RHHBF
RHHBF
Roche Holding AG
$415.00
-0.84%
 RHHBY
RHHBY
Roche Holding AG
$50.99
-0.08%
 AZN
AZN
AstraZeneca PLC
$201.21
-1.55%
 NVS
NVS
Novartis AG
$152.08
-0.85%
 MRK
MRK
Merck & Co., Inc.
$117.90
-1.72%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message